Leaflet NAABAK 49mg / ml ophthalmic drops solution


Indicated for: allergic conjunctivitis

Route of administration: ophthalmic

Substance: n-acetyl aspartyl glutamic acid (antiallergic agent)

ATC: S01GX03 (Sensory organs | Decongestants and antiallergics | Other antiallergics)

N-Acetylaspartylglutamic acid (NAAG) is a dipeptide composed of N-acetylaspartic acid and glutamic acid, naturally present in the central nervous system. It is considered a neurotransmitter or neuromodulator involved in regulating neuronal functions, playing an important role in cognitive processes, memory, and neuroprotection.

NAAG acts by binding to metabotropic glutamate receptors (mGluR3), where it can reduce the excessive release of glutamate, an excitatory neurotransmitter that, in high amounts, can cause neurotoxicity. It also has potential neuroprotective and anti-inflammatory properties and is being investigated for its use in conditions such as multiple sclerosis, Alzheimer’s disease, neuropathic pain, and other neurological disorders.

Although it is a promising substance, its therapeutic use is still under research, and its safety and efficacy are not yet fully established. Any use should be supervised by a specialist.

General data about NAABAK 49mg / ml

  • Substance: n-acetyl aspartyl glutamic acid
  • Date of last drug list: 01-07-2013
  • Commercial code: W43641001
  • Concentration: 49mg / ml
  • Pharmaceutical form: ophthalmic drops solution
  • Packing volume: 10 ml
  • Product type: generic
  • Prescription restrictions: OTC - Over the Counter = medicines that do not require a prescription.

Marketing authorisation

  • Manufacturer: THISSEN LABORATOIRES SA - BELGIA
  • Holder: LABORATOIRES THEA - FRANTA
  • Number: 12887/2019/01
  • Shelf life: 2 years